Roche CEO Addresses Swiss Franc Strength and U.S. Investment Strategy Amid Sales Decline
Roche reported a 5% year-on-year decline in first-quarter sales, attributed to the strength of the Swiss franc and generic competition. However, sales increased by 6% on a constant currency basis. CEO Thomas Schinecker emphasized the importance of U.S. dollar-based reporting, noting a 9% increase in U.S. dollar sales.
Topics: CT-388 currency impact pharmaceutical industry Roche sales decline